A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Poziotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 30 Nov 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 30 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 08 Dec 2015 According to a Spectrum Pharmaceuticals media release, data from this study will be presented at the San Antonio Breast Cancer Symposium (SABCS) 2015.